- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Biogen Idec (NASDAQ: BIIB) will be releasing their earnings report tomorrow morning before the opening bell. The First Call consensus estimates are that Biogen (BIIB) will report earnings per share of $1.05 versus $0.93 in the year ago period. In today's trading, the stock fell 1.29% to close at $52.84.
Biogen Idec Inc. (BIIB) is engaged in the development, manufacturing, and commercialization of therapies. The Company’s products address diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease and psoriasis. The company's current market cap is $15.28 billion.